AER 1504234 is a spontaneous case, received on 30/Aug/2013 from a physician via company representative and 
concerns a female patient of an unknown age who developed progressive multifocal leukoencephalopathy while 
being treated with rituximab (Mabthera).
Patient`s medical history, concurrent conditions, concomitant medications and past drugs were not reported.
On an unspecified date, the patient started therapy with rituximab (route, form, frequency and dose were not 
reported) for follicular non-hodgkin's lymphoma. Later, she developed progressive multifocal leukoencephalopathy. 
On /Jan/2014, therapy with rituximab was stopped.
At the time of the report, outcome of event progressive multifocal leukoencephalopathy was not reported.
The reporter did not assess the causality of event progressive multifocal leukoencephalopathy with rituximab.
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 164 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The company assessed event progressive multifocal leukoencephalopathy as medically significant.
No further information was provided.